Recent Updates
Recently added Catalysts
A Positive Sentiment

Agilent to Participate in J.P. Morgan U.S. All Stars Conference

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agilent Technologies Inc. announced its participation in the J.P. Morgan U.S. All Stars Conference. CEO Padraig McDonnell and CFO Adam Elinoff will engage in a fireside chat scheduled for September 23, 2026, in London. The event will be accessible via a live audio webcast on Agilent's Investor Relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agilent's participation highlights its leadership in the industry.
  • The event provides a platform for Agilent's executives to engage with investors.
  • Live audio webcast allows broader access to the presentation.

Full Press Release Details

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference. The event is scheduled for 10 a.m. BST on Wednesday, Sept. 23, 2026, in London. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader

Frequently Asked Questions

When is Agilent's participation in the conference?

Agilent will participate in the conference on September 23, 2026.

Who will represent Agilent at the conference?

CEO Padraig McDonnell and CFO Adam Elinoff will represent Agilent.

Where will the J.P. Morgan conference take place?

The conference will be held in London.

Will the presentation be available online?

Yes, a live audio webcast will be available on Agilent's Investor Relations website.

ShareAdd on Google
Tags: A Viatris Investor Conferences Healthcare Agilent Technologies J.P. Morgan Padraig McDonnell CFO Adam Elinoff London
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$1758M liquidity · $0M/mo burn
Low dilution risk